58 related articles for article (PubMed ID: 15506976)
1. Epigenetic approaches to cancer therapy.
Plumb JA; Steele N; Finn PW; Brown R
Biochem Soc Trans; 2004 Dec; 32(Pt 6):1095-7. PubMed ID: 15506976
[TBL] [Abstract][Full Text] [Related]
2. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
El-Khoury V; Breuzard G; Fourré N; Dufer J
Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
Qiu YY; Mirkin BL; Dwivedi RS
Cancer Detect Prev; 2005; 29(5):456-63. PubMed ID: 16185816
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
Digel W; Lübbert M
Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
[TBL] [Abstract][Full Text] [Related]
8. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
[TBL] [Abstract][Full Text] [Related]
9. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin represses transcriptional activity from the minimal promoter of the O6-methylguanine methyltransferase gene and increases sensitivity of human gallbladder cancer cells to 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-2-chloroethyl)-3-nitrosourea.
Sato K; Kitajima Y; Nakagawachi T; Soejima H; Miyoshi A; Koga Y; Miyazaki K
Oncol Rep; 2005 May; 13(5):899-906. PubMed ID: 15809756
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
15. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
Stordal B; Peters G; Davey R
Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
17. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
[TBL] [Abstract][Full Text] [Related]
18. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
[TBL] [Abstract][Full Text] [Related]
20. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
